BALPHARMA.BOBALPHARMA.BOBSE
Loading
Operating Expenses Over TimeExpanding
Percentile Rank67
3Y CAGR-6.3%
5Y CAGR+14.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-6.3%/yr
vs +3.8%/yr prior
5Y CAGR
+14.2%/yr
Recent deceleration
Acceleration
-10.1pp
Decelerating
Percentile
P67
Within normal range
vs 5Y Ago
1.9x
Solid growth
Streak
1 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $888.51M | +124.4% |
| 2025 | $396.01M | -0.2% |
| 2024 | $396.65M | -63.2% |
| 2023 | $1.08B | +11.5% |
| 2022 | $967.88M | +111.6% |
| 2021 | $457.34M | -48.1% |
| 2020 | $881.02M | -5.3% |
| 2019 | $929.88M | -3.7% |
| 2018 | $965.21M | -7.3% |
| 2017 | $1.04B | - |